SCHEMBL3882048

SCHEMBL3882048

COC(=O)CCc1ccc(OCC2CCCC2)c(-c2ccc3cc(N(C)C)ccc3c2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
C5AR1 P21730 1/20 0.38
ABL1 P00519 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
PTPN1 P18031 2/20 0.37
CCNC P24863 1/20 0.37
CDK8 P49336 1/20 0.37
SRC P12931 3/20 0.36
FFAR4 Q5NUL3 2/20 0.36
S1PR1 P21453 1/20 0.36
THRA P10827 1/20 0.35
THRB P10828 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CNR1 P21554 2/20 0.35
PARP15 Q460N3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3883134 0.91 FFAR4 (0.46) C5AR1ABL1SRCFFAR4S1PR1
SCHEMBL3883719 0.89 CCNC (0.48) MEN1KMT2AC5AR1HRH3PTPN1
SCHEMBL3681581 0.88 MEN1 (0.41) MEN1KMT2AC5AR1HRH3PTPN1
SCHEMBL3686084 0.87 C5AR1 (0.41) MEN1KMT2AC5AR1HRH3PTPN1
SCHEMBL3887753 0.87 MEN1 (0.42) MEN1KMT2AC5AR1HRH3PTPN1
SCHEMBL3887867 0.86 C5AR1 (0.42) MEN1KMT2AC5AR1ABL1HRH3
SCHEMBL3884610 0.86 ALDH1A1 (0.43) MEN1KMT2APTPN1SRCPDE4D
SCHEMBL3892678 0.85 MEN1 (0.41) MEN1KMT2AC5AR1HRH3SRC
SCHEMBL3882079 0.85 SRC (0.42) MEN1KMT2AC5AR1HRH3CCNC
SCHEMBL3675705 0.85 MEN1 (0.38) MEN1KMT2AC5AR1SRCFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US claimed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP claimed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US claimed
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP disclosed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US disclosed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP disclosed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof PTGER1, CYSLTR1, PTGS1 MEN1 4756/4885KMT2A 2392/4885C5AR1 282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.